GO:0045131 pre-mRNA branch point binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045131 (pre-mRNA branch point binding) is a molecular function describing the binding of proteins or ribonucleoproteins to the branch point sequence located upstream of the 3' splice site in pre-mRNA.
• The branch point adenosine is the nucleophile that initiates the first catalytic step of pre-mRNA splicing, making its recognition essential for spliceosome assembly and fidelity.
• U2 snRNP, U2AF65, SF3b155, and a 28-kDa spliceosome-associated protein sequentially recognize the branch point, with competition for the conserved sequence influencing physiological splicing outcomes [3,6,7].
• Mutations in branch point sequences, such as those in the XPC gene, disrupt U2 snRNP binding and cause abnormal pre-mRNA splicing in xeroderma pigmentosum patients.
• Polypyrimidine tract binding protein (PTBP1) can inhibit IgM pre-mRNA splicing by diverting U2 snRNA base-pairing away from the branch point.
• CRISPR-based knockout, point mutation, and knock-in models enable functional dissection of branch point binding factors and their roles in disease [1,3].
Description
Pre-mRNA branch point binding (GO:0045131) is a molecular function that governs the initial recognition of the branch point sequence during spliceosome assembly. The branch point is a conserved adenosine residue located upstream of the 3' splice site, and its binding by U2 snRNP components is a prerequisite for the first transesterification reaction of splicing. This function is critical for accurate exon definition and for the fidelity of mRNA maturation in eukaryotic cells. Researchers study pre-mRNA branch point binding to understand how splice site selection is regulated and how mutations in branch point sequences or in the proteins that recognize them contribute to human disease [3,4]. For example, branch point mutations in the XPC gene impair U2 snRNP binding and lead to aberrant splicing in xeroderma pigmentosum. Additionally, competition for the conserved branch point sequence can influence physiological outcomes, highlighting the regulatory complexity of this interaction. The molecular players involved include U2AF65, SF3b155, p14, and a 28-kDa spliceosome-associated protein, which sequentially engage the branch point to define the 3' splice site [6,7]. Understanding these interactions at atomic and cellular resolution is essential for developing therapeutic strategies that target splicing in cancer and genetic disorders [1,3].
pre-mRNA branch point binding At A Glance
| GO ID | GO:0045131 |
|---|---|
| GO term | pre-mRNA branch point binding |
| Ontology | molecular_function |
| Synonym | None |
| Major function | Binding to the branch point sequence upstream of the 3' splice site to initiate spliceosome assembly |
| Key molecular players | U2 snRNP, U2AF65, SF3b155, p14, 28-kDa protein [6,7] |
| Substrate | Pre-mRNA containing a branch point adenosine |
| Associated process | Pre-mRNA splicing via spliceosome |
| Disease relevance | Xeroderma pigmentosum, cancer, splicing-related disorders |
What Is GO:0045131?
GO:0045131, pre-mRNA branch point binding, is defined as the binding to a pre-mRNA branch point sequence, which is located upstream of the 3' splice site. This molecular function is carried out by proteins and ribonucleoprotein complexes that specifically recognize the branch point adenosine and its flanking nucleotides, thereby positioning the branch point for nucleophilic attack during the first step of splicing [1,6].
Why Is pre-mRNA branch point binding Important in Cell Biology?
Pre-mRNA branch point binding is a decisive step in spliceosome assembly because it defines the branch point adenosine that initiates the first catalytic step of splicing. Errors in this process can lead to intron retention, exon skipping, or activation of cryptic splice sites, which are associated with a wide range of human diseases, including cancer and genetic disorders such as xeroderma pigmentosum. Moreover, the competition for the conserved branch point sequence among splicing factors can modulate physiological outcomes, making this function a key node for regulatory control.
• Defines the branch point adenosine for the first transesterification reaction in splicing.
• Essential for accurate 3' splice site selection and exon definition.
• Mutations in branch point sequences disrupt U2 snRNP binding and cause aberrant splicing in xeroderma pigmentosum.
• PTBP1 inhibits IgM pre-mRNA splicing by diverting U2 snRNA base-pairing away from the branch point.
• Competition for the branch point sequence influences physiological splicing outcomes.
• Sequential recognition by U2AF65 and a 28-kDa protein ensures fidelity of branch point selection.
• SF3b155, p14, and U2AF form a network that defines the branch point during spliceosome assembly.
• Interplay between U2 snRNP and 3' splice factors affects branch point selection on beta-globin pre-mRNA.
• Dysregulation of branch point binding is linked to cancer and splicing-related diseases [1,4].
• CRISPR-based models enable functional interrogation of branch point binding factors [1,3].
What Happens During pre-mRNA branch point binding?
Initial recognition of the branch point sequence
In simple terms: The cell first identifies the branch point adenosine in the pre-mRNA.
The branch point sequence is recognized early during spliceosome assembly, with U2AF65 binding to the polypyrimidine tract and the branch point region to help define the 3' splice site. This initial recognition is critical for subsequent U2 snRNP engagement and for preventing aberrant splicing.
U2 snRNP engagement and base-pairing
In simple terms: U2 snRNP then base-pairs with the branch point to lock it in place.
U2 snRNP interacts with the branch point sequence, and its snRNA base-pairs with the pre-mRNA to position the branch point adenosine for catalysis. This step is ATP-dependent and involves multiple protein factors, including SF3b155 and p14, which stabilize the interaction network.
Sequential factor exchange and proofreading
In simple terms: Other proteins join and leave to ensure the right branch point is chosen.
A 28-kDa spliceosome-associated protein acts after U2AF65 to sequentially recognize the branch point, contributing to proofreading and fidelity. Competition for the conserved branch point sequence among different factors can influence which branch point is used, affecting physiological outcomes.
Regulation by inhibitory factors
In simple terms: Some proteins can block branch point recognition to control splicing.
Polypyrimidine tract binding protein (PTBP1) inhibits IgM pre-mRNA splicing by diverting U2 snRNA base-pairing away from the branch point, demonstrating that branch point binding is a regulated step. Similarly, interplay between U2 snRNP and 3' splice factors can modulate branch point selection on human beta-globin pre-mRNA.
Consequences for 3' splice site selection
In simple terms: The branch point choice ultimately determines where the 3' splice site is cut.
The binding of factors to the branch point is coupled to 3' splice site selection, and mutations that disrupt this binding can lead to abnormal splicing patterns. This coupling ensures that the branch point adenosine is correctly positioned relative to the 3' splice site for efficient catalysis.
Key Genes Involved in GO:0045131 pre-mRNA branch point binding
The following genes and proteins are central to pre-mRNA branch point binding and its regulation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| U2AF1 | Encodes U2AF35, part of U2AF heterodimer that binds the polypyrimidine tract and branch point region | Mutations in U2AF1 are found in cancers and affect branch point recognition |
| U2AF2 | Encodes U2AF65, which binds the polypyrimidine tract and interacts with the branch point | Key factor for initial branch point recognition and 3' splice site definition |
| SF3B1 | Encodes SF3b155, a component of U2 snRNP that contacts the branch point | Mutations in SF3B1 are common in myelodysplastic syndromes and affect branch point selection |
| SF3B2 | Encodes SF3b145, part of the SF3b complex | Contributes to U2 snRNP stability and branch point recognition |
| SF3B3 | Encodes SF3b130, part of the SF3b complex | Involved in branch point definition and spliceosome assembly |
| SF3B4 | Encodes SF3b49, part of the SF3b complex | Mutations cause Nager syndrome and affect splicing |
| SF3B5 | Encodes SF3b10, part of the SF3b complex | Small subunit of SF3b involved in branch point recognition |
| SF3B6 | Encodes p14, which interacts with SF3b155 and U2AF | Biochemical and NMR studies show its role in branch point definition |
| U2SURP | Encodes a 28-kDa spliceosome-associated protein | Sequentially recognizes the branch point after U2AF65 |
| PTBP1 | Polypyrimidine tract binding protein 1 | Inhibits IgM pre-mRNA splicing by diverting U2 snRNA from the branch point |
| XPC | Xeroderma pigmentosum group C gene | Branch point mutations disrupt U2 snRNP binding and cause abnormal splicing |
| HBB | Beta-globin gene | Model for studying branch point selection and U2 snRNP interplay |
| U2 snRNA | Non-coding RNA component of U2 snRNP | Base-pairs with the branch point sequence |
| DDX46 | RNA helicase involved in spliceosome assembly | Facilitates U2 snRNP dynamics at the branch point |
| PRPF8 | Component of the U5 snRNP and spliceosome | Interacts with branch point region during activation |
| SNRPB | Encodes SmB/B' proteins of snRNPs | Core component of U2 snRNP |
| RBM39 | RNA binding motif protein 39 | Associated with U2AF and branch point recognition |
| CWC22 | Spliceosome component | Involved in exon junction complex and branch point recognition |
How Is pre-mRNA branch point binding Regulated?
Pre-mRNA branch point binding is regulated by competition among splicing factors for the conserved branch point sequence, which can influence physiological outcomes. For example, PTBP1 can inhibit splicing by diverting U2 snRNA base-pairing away from the branch point. Additionally, the interplay between U2 snRNP and 3' splice factors modulates branch point selection on specific pre-mRNAs such as beta-globin. These regulatory mechanisms ensure flexibility in splice site choice in response to cellular signals.
pre-mRNA branch point binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| XPC | Xeroderma pigmentosum with abnormal splicing due to branch point mutations | Knock-in of patient branch point mutation in cell lines |
| SF3B1 | Myelodysplastic syndromes and cancers with altered branch point selection | Knockout and point mutation models in hematopoietic cells |
| U2AF1 | Cancers with mutations affecting branch point recognition | Knock-in of U2AF1 mutations in cell lines |
| PTBP1 | Regulation of IgM splicing and neuronal differentiation | Overexpression and knockout in B cells and neurons |
| HBB | Beta-thalassemia with branch point mutations | Knock-in of beta-globin branch point mutations |
Xeroderma pigmentosum and branch point mutations
Mutations in the branch point sequence of the XPC gene disrupt U2 snRNP binding, resulting in abnormal pre-mRNA splicing in xeroderma pigmentosum patients. This highlights how branch point recognition defects can cause inherited diseases.
Cancer and splicing factor mutations
Mutations in splicing factors such as SF3B1 and U2AF1, which are involved in branch point recognition, are frequently found in cancers and myelodysplastic syndromes. These mutations can alter branch point selection and promote oncogenic splicing patterns.
Neurological and developmental disorders
Dysregulation of branch point binding factors can affect neuronal splicing and development, as seen in diseases linked to SF3B4 mutations such as Nager syndrome. The precise recognition of branch points is essential for normal development.
From pre-mRNA branch point binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the effect of a branch point mutation on splicing? | Point mutation knock-in in cell lines |
| Which factors are essential for branch point binding? | CRISPR knockout of U2AF2, SF3B1, or PTBP1 [1,5] |
| How does a disease-associated mutation alter branch point selection? | Knock-in of patient mutations in SF3B1 or U2AF1 |
| Where does branch point binding occur in the nucleus? | Tagged knock-in of splicing factors with fluorescent proteins |
| Can overexpression of a factor rescue splicing defects? | Overexpression of wild-type or mutant U2AF65 |
| What are the genome-wide consequences of branch point dysregulation? | CRISPR library screening and RNA-seq [1,3] |
How to Study the pre-mRNA branch point binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global splicing changes and branch point usage | Knockout or mutation models |
| CLIP-seq | Protein-RNA binding sites at branch points | Mapping U2AF65 or SF3B1 interactions [1,6] |
| In vitro splicing | Splicing efficiency and branch point selection | Testing mutant pre-mRNA substrates |
| NMR spectroscopy | Molecular interactions in branch point recognition | Structural studies of SF3b155-p14-U2AF-RNA |
| CRISPR screening | Identification of genes required for branch point binding | Genome-wide knockout libraries |
| Proteomics | Composition of spliceosomal complexes | Affinity purification of U2 snRNP |
| Single-molecule imaging | Dynamics of branch point recognition | Live-cell tracking of splicing factors |
| Bioinformatics | Prediction of branch point sequences | Genome-wide annotation of branch points |
RNA-seq and splicing analysis
RNA sequencing can detect changes in splicing patterns, including intron retention and exon skipping, caused by alterations in branch point binding. Computational tools can map branch points and quantify their usage.
CLIP-seq and RIP-seq
Crosslinking and immunoprecipitation followed by sequencing (CLIP-seq) can identify the RNA binding sites of proteins involved in branch point recognition, such as U2AF65 and SF3B1 [1,6].
In vitro splicing assays
In vitro splicing assays using radiolabeled pre-mRNA and nuclear extracts can directly test the requirement for branch point binding factors and the effects of mutations.
Structural biology and NMR
NMR and crystallography studies have revealed the interaction network of SF3b155, p14, and U2AF with the branch point RNA, providing mechanistic insights.
How CRISPR Can Be Used to Study GO:0045131 pre-mRNA branch point binding
Knockout
CRISPR knockout of genes encoding branch point binding factors, such as U2AF2 or SF3B1, can reveal their essential roles in splicing and cell viability. Knockout models are useful for identifying which factors are required for branch point recognition.
Point Mutation
Point mutations can be introduced into branch point sequences or into the genes of splicing factors to mimic disease-associated variants, such as those in XPC or SF3B1. These models help dissect the functional consequences of specific mutations.
Knock-in
Knock-in of tagged versions of branch point binding proteins, such as fluorescently labeled U2AF65, allows visualization of their localization and dynamics in living cells. Knock-in of patient mutations can create disease models.
Overexpression
Overexpression of wild-type or mutant branch point binding factors can test gain-of-function effects and rescue experiments. For example, overexpression of PTBP1 can inhibit splicing by diverting U2 snRNA.
How EDITGENE Supports pre-mRNA branch point binding Research
Researchers studying pre-mRNA branch point binding-related genes often need to determine whether a candidate gene is causally involved in splicing regulation or disease. EDITGENE provides comprehensive CRISPR-based services to generate knockout, point mutation, knock-in, and overexpression cell models, as well as library screening and bioinformatics support, enabling precise functional interrogation of branch point binding factors.
Contact EDITGENE today to design your custom CRISPR model for pre-mRNA branch point binding research.
Frequently Asked Questions About pre-mRNA branch point binding
What is pre-mRNA branch point binding?
Pre-mRNA branch point binding (GO:0045131) is the molecular function of binding to the branch point sequence located upstream of the 3' splice site in pre-mRNA, a key step in spliceosome assembly.
What genes are involved in pre-mRNA branch point binding?
Key genes include U2AF1, U2AF2, SF3B1, SF3B2, SF3B3, SF3B4, SF3B5, SF3B6, PTBP1, and XPC, among others [1,4,5,6,7].
How does branch point recognition affect splicing?
Recognition of the branch point adenosine by U2 snRNP and associated factors is required for the first catalytic step of splicing; errors can lead to intron retention or exon skipping.
What diseases are associated with defects in branch point binding?
Mutations in branch point sequences or splicing factors can cause xeroderma pigmentosum, cancers, and developmental disorders such as Nager syndrome [1,4].
Which proteins bind the branch point sequence?
U2AF65, SF3b155, p14, a 28-kDa spliceosome-associated protein, and U2 snRNP components bind the branch point sequence [6,7].
How is branch point binding regulated?
It is regulated by competition among splicing factors for the conserved branch point sequence and by inhibitory proteins such as PTBP1 [3,5].
What methods are used to study pre-mRNA branch point binding?
Common methods include RNA-seq, CLIP-seq, in vitro splicing assays, NMR, and CRISPR-based screens [1,6,7,8].
Can CRISPR be used to study branch point binding?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models enable functional dissection of branch point binding factors [1,3].
What is the role of U2 snRNP in branch point binding?
U2 snRNP base-pairs with the branch point sequence to position the branch point adenosine for catalysis.
Why is the branch point sequence conserved?
The branch point adenosine is the nucleophile for the first splicing reaction, so its sequence is under selective pressure to ensure efficient and accurate splicing [1,3].
Conclusion
Pre-mRNA branch point binding (GO:0045131) is a fundamental molecular function that ensures accurate spliceosome assembly and splicing fidelity. Its dysregulation is linked to human diseases, including xeroderma pigmentosum and cancer, making it a critical area of research. Advances in CRISPR-based models and high-throughput methods continue to illuminate the mechanisms and regulatory networks governing branch point recognition [1,3].
References
- 1. Wilkinson ME et al.. 2020. RNA Splicing by the Spliceosome.. Annu Rev Biochem 89:359-388 PMID: 31794245
- 3. Pereira de Castro KL et al.. 2026. Competition for the conserved branch point sequence influences physiological outcomes in pre-mRNA splicing.. Elife 13 PMID: 41860977
- 4. Khan SG et al.. 2010. XPC branch-point sequence mutations disrupt U2 snRNP binding, resulting in abnormal pre-mRNA splicing in xeroderma pigmentosum patients.. Hum Mutat 31(2):167-75 PMID: 19953607
- 5. Zheng X et al.. 2014. Polypyrimidine tract binding protein inhibits IgM pre-mRNA splicing by diverting U2 snRNA base-pairing away from the branch point.. RNA 20(4):440-6 PMID: 24572809
- 6. Gaur RK et al.. 1995. Sequential recognition of the pre-mRNA branch point by U2AF65 and a novel spliceosome-associated 28-kDa protein.. RNA 1(4):407-17 PMID: 7493318
- 7. Spadaccini R et al.. 2006. Biochemical and NMR analyses of an SF3b155-p14-U2AF-RNA interaction network involved in branch point definition during pre-mRNA splicing.. RNA 12(3):410-25 PMID: 16495236
- 8. Alibert C et al.. 1990. Interplay between U2 snRNP and 3' splice factor(s) for branch point selection on human beta-globin pre-mRNA.. Nucleic Acids Res 18(2):235-45 PMID: 2139208
